$u-mv t-|bom- t om|u-1| !;v;-u1 - Atuka · bm] "|u;;| );v| $ouom|o 7 m|-ubo * -m-7- _om; ³ u u u -...
Transcript of $u-mv t-|bom- t om|u-1| !;v;-u1 - Atuka · bm] "|u;;| );v| $ouom|o 7 m|-ubo * -m-7- _om; ³ u u u -...
-
Cognition – primate models
TranslationalContract Research
Our cognition services use two platforms for cognitive testing in non-humanprimates. The Cambridge Neuropsychological Test Automated Battery(CANTAB) and the object retrieval task (OR).
Available non-human primate models
Non-human primate CANTAB
• Automated, computerized testing• Standardized testing using analogs of human
tests• Inter & intra animal reproducibility• Precise timing• Not subject to investigator bias• Well suited for drug testing• Tests of attention, spatial and non-spatial
working memory, visual memory and executive function available
Object retrieval in non-human primates
The object retrieval task (OR) innon-human primates assessesattention, response inhibition(impulsivity) and planning(frontal/frontostriatal functioning).
Normal young adult macaques –To test cognitive effects (positive or negative) of any compound
Chronic low-dose MPTP-treated macaques –Model of cognitive deficits in Parkinson’s disease,
Scopolamine-treated young adult macaques –Model of cognitive deficits in Alzheimer’s disease
Normal aged macaques (18 – 25 years old) –Model of cognitive deficits in mild cognitive impairment (MCI) and Alzheimer’s disease
-
100 King Street West
Toronto , Ontario M5X 1C9
Canada
Phone +1 416 603 5369
Fax +1 416 603 5447
Website www.atuka.com
Chronic low-dose MPTP treatmentinduces cognitive deficits in non-humanprimates. In this example, CLD-MPTPtreatment induces deficits on objectretrieval task that assesses aspects ofexecutive function. These deficits aresimilar to those seen in Parkinson’sdisease patients.
Chronic low-dose MPTP treatmentinduces cognitive deficits in non-humanprimates. In this example, CLD-MPTPtreatment induces deficits on theCANTAB VDR task that assesses aspectsof attention and memory. These deficitsare similar to those seen in Parkinson’sdisease patients.
Experimental readouts
Behavioural - Additional behavioural endpoints including home-cage activity, observation-cage activity and fine motor control can be added to cognition studies. If appropriate,specialised assessments such as the monkey parkinsonian disability rating scale, the monkeyequivalent of the clinical rating scale used to assess disability in people with Parkinson’sdisease, can also be added.
Imaging - We offer both MRI and PET imaging that allows longitudinal measurement ofmarkers of function and metabolism. In addition, novel PET ligands can be developed by ourradiochemistry team.
Pharmacokinetics, safety and blood chemistry - Can be incorporated into all studies. Blood andCSF can be sampled throughout the study and terminal samples of brain and other tissues canbe collected. Functional observational battery and blood chemistry can be used to assess off-target effects and adverse effects.
Post-mortem - We have extensive expertise in a range of post-mortem analyses includingimmunohistochemistry, ligand binding, stereology, HPLC and ELISA. Additional post-mortemmeasures can be incorporated at the request of the client.
normal MPTP normal MPTP
0
2
4
6
8
10
barr
ier r
each
es
easy trials hard trials
*
0
20
40
60
80
100%
cor
rect
resp
onse
s
2 5 10
delay duration (sec)
20 30
*
baselineCLD MPTP
** *
##
#